Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.
Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.
复制标题
DOI:
10.1016/j.nbd.2010.04.011
复制
发表时间:
2010-08
影响因子:
6.1
通讯作者:
Butterfield DA
中科院分区:
文献类型:
--
作者:
Aluise CD;Robinson RA;Beckett TL;Murphy MP;Cai J;Pierce WM;Markesbery WR;Butterfield DA
Alzheimer disease (AD) is a neurodegenerative disorder characterized clinically by progressive memory loss and subsequent dementia and neuropathologically by senile plaques, neurofibrillary tangles, and synapse loss. Interestingly, a small percentage of individuals with normal antemortem psychometric scores meet the neuropathological criteria for AD (termed `preclinical' AD (PCAD)). In this study, inferior parietal lobule (IPL) from PCAD and control subjects were compared for oxidative stress markers by immunochemistry, amyloid beta-peptide by ELISA, and identification of protein expression differences by proteomics. We observed a significant increase in highly insoluble monomeric Aβ42, but no significant differences in oligomeric Aβ nor in oxidative stress measurements between controls and PCAD subjects. Expression proteomics identified proteins whose trends in PCAD are indicative of cellular protection, possibly correlating with previous studies showing no cell loss in PCAD. Our analyses may reveal processes involved in a period of protection from neurodegeneration that mimic the clinical phenotype of PCAD.
登录
查看更多内容
影响因子:
2
作者:
Howlett, D. R.;Bowler, K.;Richardson, J. C.
通讯作者:
Richardson, J. C.
影响因子:
82.9
作者:
Geula, C;Wu, CK;Yankner, BA
通讯作者:
Yankner, BA
影响因子:
4.8
作者:
Higaki, J;Catalano, R;Cordell, B
通讯作者:
Cordell, B
DOI:
10.1073/pnas.0705738104
发表时间:
2007-08-28
影响因子:
11.1
作者:
Fukui, Hirokazu;Diaz, Francisca;Moraes, Carlos T.
通讯作者:
Moraes, Carlos T.
影响因子:
3.1
作者:
Aksenov, MY;Tucker, HM;Markesbery, WR
通讯作者:
Markesbery, WR